Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr;21(3):e00351.
doi: 10.1016/j.neurot.2024.e00351. Epub 2024 Mar 25.

Extended interval dosing of natalizumab: More evidence in support

Affiliations
Editorial

Extended interval dosing of natalizumab: More evidence in support

Karlo Toljan et al. Neurotherapeutics. 2024 Apr.
No abstract available

Keywords: Disease-modifying therapy; Extended interval dosing; Multiple sclerosis; Natalizumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Devon Conway reports a relationship with Bristol Myers Squibb Co that includes: consulting or advisory and funding grants. Devon Conway reports a relationship with Biogen Inc that includes: funding grants and speaking and lecture fees. Karlo Toljan reports a relationship with National Multiple Sclerosis Society that includes: funding grants. Devon Conway reports a relationship with Novartis Pharmaceuticals Corporation that includes: consulting or advisory and funding grants. Devon Conway reports a relationship with Horizon Therapeutics USA Inc that includes: funding grants. Devon Conway reports a relationship with Alexion that includes: consulting or advisory. Devon Conway reports a relationship with EMD Serono Inc that includes: funding grants. Devon Conway reports a relationship with US Department of Defense that includes: funding grants. Devon Conway reports a relationship with TG Therapeutics Inc that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Polman C.H., O’Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910. - PubMed
    1. Rudick R.A., Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004;4:571–580. - PubMed
    1. Vukusic S., Rollot F., Casey R., Pique J., Marignier R., Mathey G., et al. Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France. JAMA Neurol. 2020;77:94. - PMC - PubMed
    1. Ryerson L.Z., Foley J., Chang I., Kister I., Cutter G., Metzger R.R., et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93 - PMC - PubMed
    1. Zhovtis Ryerson L., Li X., Goldberg J.D., Hoyt T., Christensen A., Metzger R.R., et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm. 2020;7:e672. - PMC - PubMed

Publication types

MeSH terms